Phathom Pharmaceuticals Analyst Ratings
Needham: Reiterated Phathom Pharmaceuticals (PHAT.US) rating and adjusted from buy to buy rating, target price of $26.00.
Phathom Pharmaceuticals Analyst Ratings
Needham Reiterates Buy on Phathom Pharmaceuticals, Maintains $26 Price Target
Analysts Offer Insights on Healthcare Companies: PMV Pharmaceuticals (PMVP) and Phathom Pharmaceuticals (PHAT)
Craig-Hallum Remains a Buy on Phathom Pharmaceuticals (PHAT)
HC Wainwright & Co. : The Phathom Pharmaceuticals (PHAT.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $28.00.
HC Wainwright & Co. Reiterates Buy on Phathom Pharmaceuticals, Maintains $28 Price Target
Phathom Pharmaceuticals Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (PHAT), ACELYRIN, INC. (SLRN) and Moderna (MRNA)
Needham: Reiterated Phathom Pharmaceuticals (PHAT.US) rating and adjusted from buy to buy rating, target price of $26.00.
Phathom Pharmaceuticals Analyst Ratings
Needham Reiterates Buy on Phathom Pharmaceuticals, Maintains $26 Price Target
Needham: Reiterated Phathom Pharmaceuticals (PHAT.US) rating and adjusted from buy to buy rating, target price of $26.00.
Needham Reiterates Buy on Phathom Pharmaceuticals, Maintains $26 Price Target
Phathom Pharmaceuticals Analyst Ratings
Buy Rating Affirmed for Phathom Pharmaceuticals on V Oquezna's Promising Market Trajectory
Phathom Pharmaceuticals (PHAT.US) was first covered by Stifel, giving it a buy rating, with a target price of $24.00.
Phathom Pharmaceuticals Analyst Ratings
Phathom Pharmaceuticals Analyst Ratings
No Data